161 related articles for article (PubMed ID: 29933048)
1. Agave negatively regulates YAP and TAZ transcriptionally and post-translationally in osteosarcoma cell lines.
Ferraiuolo M; Pulito C; Finch-Edmondson M; Korita E; Maidecchi A; Donzelli S; Muti P; Serra M; Sudol M; Strano S; Blandino G
Cancer Lett; 2018 Oct; 433():18-32. PubMed ID: 29933048
[TBL] [Abstract][Full Text] [Related]
2. Hippo/YAP signaling pathway is involved in osteosarcoma chemoresistance.
Wang DY; Wu YN; Huang JQ; Wang W; Xu M; Jia JP; Han G; Mao BB; Bi WZ
Chin J Cancer; 2016 May; 35():47. PubMed ID: 27206784
[TBL] [Abstract][Full Text] [Related]
3. ROCK2 deprivation leads to the inhibition of tumor growth and metastatic potential in osteosarcoma cells through the modulation of YAP activity.
Zucchini C; Manara MC; Cristalli C; Carrabotta M; Greco S; Pinca RS; Ferrari C; Landuzzi L; Pasello M; Lollini PL; Gambarotti M; Donati DM; Scotlandi K
J Exp Clin Cancer Res; 2019 Dec; 38(1):503. PubMed ID: 31878963
[TBL] [Abstract][Full Text] [Related]
4. S1P/S1PR3 axis promotes aerobic glycolysis by YAP/c-MYC/PGAM1 axis in osteosarcoma.
Shen Y; Zhao S; Wang S; Pan X; Zhang Y; Xu J; Jiang Y; Li H; Zhang Q; Gao J; Yang Q; Zhou Y; Jiang S; Yang H; Zhang Z; Zhang R; Li J; Zhou D
EBioMedicine; 2019 Feb; 40():210-223. PubMed ID: 30587459
[TBL] [Abstract][Full Text] [Related]
5. Long non-coding RNA XIST promotes osteosarcoma progression by targeting YAP via miR-195-5p.
Yang C; Wu K; Wang S; Wei G
J Cell Biochem; 2018 Jul; 119(7):5646-5656. PubMed ID: 29384226
[TBL] [Abstract][Full Text] [Related]
6. Sensitisation of Cancer Cells to MLN8237, an Aurora-A Inhibitor, by YAP/TAZ Inactivation.
Oku Y; Nishiya N; Sugiyama S; Sato H; Uehara Y
Anticancer Res; 2018 Jun; 38(6):3471-3476. PubMed ID: 29848699
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of curcumin is involved in down-regulation of YAP/TAZ expression in pancreatic cancer cells.
Zhou X; Su J; Feng S; Wang L; Yin X; Yan J; Wang Z
Oncotarget; 2016 Nov; 7(48):79076-79088. PubMed ID: 27738325
[TBL] [Abstract][Full Text] [Related]
8. Ailanthone inhibits cell growth and migration of cisplatin resistant bladder cancer cells through down-regulation of Nrf2, YAP, and c-Myc expression.
Daga M; Pizzimenti S; Dianzani C; Cucci MA; Cavalli R; Grattarola M; Ferrara B; Scariot V; Trotta F; Barrera G
Phytomedicine; 2019 Mar; 56():156-164. PubMed ID: 30668336
[TBL] [Abstract][Full Text] [Related]
9. Knockdown of HuR represses osteosarcoma cells migration, invasion and stemness through inhibition of YAP activation and increases susceptibility to chemotherapeutic agents.
Xu W; Chen C; Xu R; Li Y; Hu R; Li Z; Zhu X
Biomed Pharmacother; 2018 Jun; 102():587-593. PubMed ID: 29597092
[TBL] [Abstract][Full Text] [Related]
10. Mechanically tunable coaxial electrospun models of YAP/TAZ mechanoresponse and IGF-1R activation in osteosarcoma.
Molina ER; Chim LK; Salazar MC; Mehta SM; Menegaz BA; Lamhamedi-Cherradi SE; Satish T; Mohiuddin S; McCall D; Zaske AM; Cuglievan B; Lazar AJ; Scott DW; Grande-Allen JK; Ludwig JA; Mikos AG
Acta Biomater; 2019 Dec; 100():38-51. PubMed ID: 31542501
[TBL] [Abstract][Full Text] [Related]
11. An evaluation of TAZ and YAP crosstalk with TGFβ signalling in canine osteosarcoma suggests involvement of hippo signalling in disease progression.
Luu AK; Schott CR; Jones R; Poon AC; Golding B; Hamed R; Deheshi B; Mutsaers A; Wood GA; Viloria-Petit AM
BMC Vet Res; 2018 Nov; 14(1):365. PubMed ID: 30477496
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of the Hippo pathway transcriptional coactivators YAP/TAZ and β1-integrin in conventional osteosarcoma.
Bouvier C; Macagno N; Nguyen Q; Loundou A; Jiguet-Jiglaire C; Gentet JC; Jouve JL; Rochwerger A; Mattei JC; Bouvard D; Salas S
Oncotarget; 2016 Oct; 7(40):64702-64710. PubMed ID: 27608849
[TBL] [Abstract][Full Text] [Related]
13. Suppression of YAP by DDP disrupts colon tumor progression.
Li K; Guo J; Wu Y; Jin D; Jiang H; Liu C; Qin C
Oncol Rep; 2018 May; 39(5):2114-2126. PubMed ID: 29512779
[TBL] [Abstract][Full Text] [Related]
14. Suppressing CHD1L reduces the proliferation and chemoresistance in osteosarcoma.
Fan GT; Ling ZH; He ZW; Wu SJ; Zhou GX
Biochem Biophys Res Commun; 2021 May; 554():214-221. PubMed ID: 33813077
[TBL] [Abstract][Full Text] [Related]
15. Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activation.
Kim MH; Kim J; Hong H; Lee SH; Lee JK; Jung E; Kim J
EMBO J; 2016 Mar; 35(5):462-78. PubMed ID: 26668268
[TBL] [Abstract][Full Text] [Related]
16. TAZ and YAP are frequently activated oncoproteins in sarcomas.
Fullenkamp CA; Hall SL; Jaber OI; Pakalniskis BL; Savage EC; Savage JM; Ofori-Amanfo GK; Lambertz AM; Ivins SD; Stipp CS; Miller BJ; Milhem MM; Tanas MR
Oncotarget; 2016 May; 7(21):30094-108. PubMed ID: 27129148
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of nuclear factor-κB by dehydroxymethylepoxyquinomicin induces schedule-dependent chemosensitivity to anticancer drugs and enhances chemoinduced apoptosis in osteosarcoma cells.
Castro-Gamero AM; Borges KS; da Silva Silveira V; Lira RC; de Paula Gomes Queiroz R; Valera FC; Scrideli CA; Umezawa K; Tone LG
Anticancer Drugs; 2012 Jul; 23(6):638-50. PubMed ID: 22382389
[TBL] [Abstract][Full Text] [Related]
18. Correlation of nuclear pIGF-1R/IGF-1R and YAP/TAZ in a tissue microarray with outcomes in osteosarcoma patients.
Molina ER; Chim LK; Lamhamedi-Cherradi SE; Mohiuddin S; McCall D; Cuglievan B; Krishnan S; Porter RW; Ingram DR; Wang WL; Lazar AJ; Scott DW; Truong DD; Daw NC; Ludwig JA; Mikos AG
Oncotarget; 2022; 13():521-533. PubMed ID: 35284040
[TBL] [Abstract][Full Text] [Related]
19. Notch pathway inhibition using DAPT, a γ-secretase inhibitor (GSI), enhances the antitumor effect of cisplatin in resistant osteosarcoma.
Dai G; Deng S; Guo W; Yu L; Yang J; Zhou S; Gao T
Mol Carcinog; 2019 Jan; 58(1):3-18. PubMed ID: 29964327
[TBL] [Abstract][Full Text] [Related]
20. A novel role for microRNA-129-5p in inhibiting ovarian cancer cell proliferation and survival via direct suppression of transcriptional co-activators YAP and TAZ.
Tan G; Cao X; Dai Q; Zhang B; Huang J; Xiong S; Zhang Yy; Chen W; Yang J; Li H
Oncotarget; 2015 Apr; 6(11):8676-86. PubMed ID: 25895125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
